Lung cancer

Case summary:

Patient A.D.S, 54 years old, male.

Diagnosis: Poorly differentiated infiltrating carcinoma of the lung with liver and brain, lung and bone metastases.

The disease was diagnosed as of May/June 2017 and was located in right upper lobe of lung. He also presented isolated lesions in other parts of the right lung and left lung. In PET in July 2017 and later MRI of the brain, metastases were detected in liver and brain. Surgery was ruled out and chemotherapy with carboplatin/paclitaxel was performed without favorable outcome. After the first cycle of three sessions, chemotherapy was suspended due to the growth of tumor lesions. The brain lesions were treated with radiosurgery.

She had received immunotherapy (Nivolumab/Ipilimumab) which was discontinued due to growth of tumor lesions. Radiotherapy was applied due to severe cough, back pain and hemoptysis.

Once the case had been analyzed by our specialists, we informed the family members about what could be expected with Escozul™ and the possibilities of achieving good results. Poorly differentiated or high-grade carcinomas tend to behave aggressively and their progression cannot always be halted or reversed.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Started on Escozul™ in January 2018.

Evolution, Follow-up and Current Results:

CT scan in January 2018, just prior to starting Escozul™, which was compared to November 2017 results, reported lung lesion of 100 mm major diameter obliterating the bronchus. Adenopathic tissue surrounding the larger right pulmonary hilum was also described. Isolated bilateral pulmonary nodules, larger in size and new pulmonary nodules of secondary appearance in the right lower lobe, not exceeding 10 mm. Presence of four lesions in the liver, three of them in segment IV and one in segment VII, the largest in segment IV measuring 41×41 mm. The one located in segment VII 36 mm.

It is impressive that the lesions are larger than those previously described.

In February 2018 he was additionally started on Gefitinib. By February the cough had subsided, no hemoptysis and no back pain.

They communicate again in March 2018 and comment that she continues to take Escozul™ since January 3 and also Gefitinib medication. She is doing very well, continues without coughing, breathing well and in very good spirits.

In July 2018 we are told that he continues to improve and attached last studies of May and June 2018. His physical condition is very good.

The studies performed were a CT scan of the brain, thorax, abdomen and pelvis, simple and contracted performed on June 1, 2018 which indicates:

Thorax: Decreased size of the LSD mass. It measures 50×44 mm (previous 65×45 mm) (it is possible that this measurement was made at the time of image analysis as the previous study did not give these values). No axillary, mediastinal or supraclavicular adenomegaly.

Abdomen: Reduction of the size of the lesions in segment IV (current 32×10 mm, previous 36×11 mm) and VII (current 13 mm, previous 25 mm). Osteoblastic lesions are also described in the bone window in T2 and T4 showing stability and in the right acetabular roof which has decreased in size.

In this case, the joint use of Escozul™ with A.D.S., in a short period of time, made it possible for A.D.S. to have a much better result than expected in these cases, with a decrease in the size of the tumor lesions.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case.

Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group October/2018

Medical Documents

LLG is a 64-year-old female patient who came to us in October 2017 with a diagnosis of early stage lung cancer. After 6 months of treatment with Escozul™ and surgery, the latest biopsy indicates no tumor present.

Case summary:

LLG was started on Escozul™ in October 2017. He came to us with a diagnosis of moderately differentiated adenocarcinoma of the right lung, pending surgery. According to tomography he presented a right lower lobe nodule 27.4mm in size. He also had a smaller nodule in the left lower lobe with an increase in size and metabolic increase of 8.8ml.

As the disease was at an early stage, she had not yet received treatment. She was asymptomatic.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In cases where the disease is in its early stages, the prospects of obtaining a positive result are much better.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

LLG started treatment with Escozul™ in October 2017.

Evolution, Follow-up and Current Results:

LLG has maintained during the time of treatment frequent communication with the doctor in charge of the case for follow-up with Escozul™.

On the last days of November 2017 she underwent surgery in which the main nodule and nearby nodes were removed.

The CT scan performed in December after surgery showed that the nodule in left lung tenacious still 8mm. It also indicated that there was a possible 50mm formation close to the surgical site. The patient continued to take Escozul™.

By January the new CT scan reported that the lesion had decreased to 34mm and that the nodule in the left lung was no longer visible.

In February, four months after treatment, the biopsy of the left lung nodule showed that it corresponded to chronic inflammatory tissue.

LLG is currently being followed up because if the current results are maintained, she could be discharged.

LLG continues to be treated with Escozul™ until 6 months after the first cancer-free test is completed.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group April/2018

Medical Documents

Estela is a 51 year old patient, who came to us in July 2017 with a diagnosis of advanced lung cancer, with multiple metastases including involvement to the brain. In the short time she has been on treatment she has managed to reduce the size of the tumor lesions.

Case summary:

We share the case Estela, 51 years old who came to us in July 2017, with a diagnosis of very advanced lung cancer.

When we received the medical documentation we were able to ascertain that Estela presented with stage IV left lung cancer, specifically adenocarcinoma, with large tumor mass in the upper lobe of the left lung and left hilum with almost complete collapse of the LSI, infiltration of adjacent mediastinal fat, infiltration of the superior aortic recess of the pericardium, multiple metastatic nodules in both lungs, paratracheal and subcarinal lymph node involvement, and possible metastasis in L3, left sacral wing and left iliac bone.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In such an advanced case, the chances of obtaining good results are not the best.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Estela started treatment with Escozul™, she was receiving chemotherapy and pending radiotherapy.

Evolution, follow-up and current results:

Despite the short time Estela has been on treatment, positive results have already begun to be seen, which represent hope for the patient and her family.

The September chest CT scan showed a reduction of the primary pulmonary lesion from 50x67mm to 45x35mm, as well as a decrease in the size of the lymph node involvement and pulmonary metastases.

In the following CT scan at the end of January 2018 at 6 months of treatment, further decrease of the primary tumor to 42x30mm is observed. The lung nodules are less than 1 cm in size. There is no mention of infiltration of superior aortic recess of the pericardium. The adenopathies are also less than 1cm in size.

So far, the disease has continued to gradually decrease in size.

The results at the moment are very positive and we hope that the evolution continues to be good, as a result of the combination of treatments that Estela is receiving.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group January/2018

Medical Documents

Marleny is a 61 year old patient, who came to us in January 2017 through her son, with a diagnosis of advanced stage lung cancer. She has been undergoing treatment with Escozul™, in addition to radiation therapy and chemotherapy.

Case summary:

We share the case of a 61-year-old female patient who came to us in January 2017 through her son, with a diagnosis of very advanced lung cancer with metastases in multiple locations.

When we received the medical documentation we were able to ascertain that Marleny presented with lung cancer, with a large tumor mass in the right hemithorax, lesion in the right tonsil, multiple costal lesions and multiple hilar and intracarinal adenopathies, extensive bone involvement in the spine and referred by the family to brain and liver involvement.

He presented vomiting, pain, oxygen requirement, general physical fatigue.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In this case the possibilities of obtaining results were not the best, due to the extensive metastatic involvement.

Each dose of Escozul™ is personalized, specific to the type of tumor and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Marleny started treatment with Escozul™ the first days of February 2017. She was undergoing radiotherapy and pending oral chemotherapy.

Evolution, Follow-up and Current Results:

In this particular case it is very important to point out that both Marleny and her whole family have worked together for her that she can recover following each treatment with discipline and keeping periodic contact with our medical part.

Marleny's symptoms were gradually improving, with a decrease in pain and therefore a reduction in painkillers, she stopped using oxygen, her appetite improved, and despite a relapse in vomiting when chemotherapy was introduced, these were also stabilized.

By May she was in good physical condition and had begun to gain weight.

In July 2017 Marleny underwent follow-up examinations, which showed that there was no presence of lesions in the brain, the examination of the abdomen and pelvis showed no focal lesions, and in the chest examination the adenopathies had disappeared, and only 2 nodules of less than 3mm in size were observed. The bone lesions remained in all the examinations, but the prognosis for future evolution according to the doctor attending the case in his country is positive.

Recently there has been detection of new bone lesions, which has led to a new increase of escozul and by the conventional part she has been indicated for radiotherapy. There are no symptoms of recurrence of the disease at any other level.

In a case as advanced as Marleny's, the results obtained with the combination of treatments are excellent, opening the doors for the patient to have a better life expectancy and above all with quality to enjoy her family.

We hope that these results will be maintained and that the bone lesions will be improved.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group November/2017

Medical Documents

Mariana is a patient who came to us in 2015 with an aggressive lung cancer that had undergone surgery and presented metastasis to lymph nodes. Two years after treatment, Mariana's scans are clean, there is no tumor lesion in her body.

Summary of the case:

We share the case of a 59-year-old patient who came to us in August 2015, with a diagnosis of operated lung cancer with metastasis to lymph nodes in the thorax.

When we received the medical documentation we were able to ascertain that Mariana had a primary cancer of the left lung, which had been operated on with a biopsy diagnosis of keratinizing squamous cell carcinoma, dedifferentiated. This type of cancer usually has a more aggressive behavior due to its greater capacity to reproduce and spread rapidly to other organs.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Mariana started treatment with Escozul™ in September 2015. She was pending to start chemotherapy.

Evolution, Follow-up and Current Results:

Mariana has been on treatment uninterruptedly and receiving periodic test results with controls on the status of the disease.

Since October 2016, the CT scans performed on Mariana show no tumors in any location. These results are maintained in the CT scan received in September 2017, confirming that Mariana has remained cancer free.

In this case the response is considered Excellent as it has been achieved, with the joint use of Escozul™ and chemotherapy, to eliminate lymph node involvement and prevent the disease from recurring, a result that has been maintained over time. Mariana remains under oncological surveillance in her country, with periodic check-ups, since with this type of cancer there is always the possibility of it appearing again.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group September/2017

Medical Documents

Plamen is a 61-year-old patient diagnosed with lung cancer with multiple metastases, detected in March 2017. She was started on Escozul™ in June 2017, and 3 months into treatment, her scans show stability of the disease with decrease of the main lesion in right lung.

Case summary:

We share the case of a 61-year-old patient who came to us in June 2017, with a diagnosis of lung cancer discovered already in advanced stage with metastases in different locations.

When we received the medical documentation we were able to ascertain that Plamen had a primary right lung cancer disseminated to the lung parenchyma, with lymph node metastasis in multiple locations in the thorax and abdomen, in the right adrenal gland and bone.

As for symptoms, he presented pain in the bones and lung area and mild cough.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Plamen started treatment with Escozul™ in June 2017. She was undergoing chemotherapy.

Evolution, Follow-up and Current Results:

Plamen has been on Escozul™ treatment for only 3 months, which is considered the time needed for it to be seen whether or not Escozul™ can have a positive effect on the patient. In this case, after three months of treatment, the new PET scan shows that the main tumor has decreased in size from 73mm to 38mm, in addition to having decreased its metabolic activity. Bone metastases have remained stable. For some lymph node lesions the metabolic activity has increased although not in size.

In this case the response is considered partial and the disease points towards stability. The decrease in the size of the main lesion has been almost 50%, which is remarkable. The combined use of Escozul™ and chemotherapy has resulted in a 3-month treatment outcome. We hope that the results will continue to improve in future controls.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group September/2017

Medical Documents

Elena is a 60-year-old patient, diagnosed in early 2017 with left lung cancer with multiple cervical and thoracic lymph node metastases. In the first 4 months of treatment with Escozul™ in conjunction with chemotherapy, she has been able to decrease the cancerous activity of the tumors and reduce the size of the lymph node metastases.

Summary of the case:

The case we share today is about a 60-year-old female patient who came to us in March 2017, with a diagnosis of newly discovered lung cancer with involvement to neck and thoracic nodes.

When we received the medical documentation we were able to ascertain that it was a left lung cancer (specifically a grade 3 adenocarcinoma), discovered as a result of the appearance of a lump in the neck, which turned out to be tumor lymph node growth (adenopathy) in the neck derived from the primary cancer in the lung. He presented a mass in the left lung and numerous lymph node metastases (adenopathies) in the thorax in addition to those present in the neck.

As for symptoms, he reported insomnia and weakness.

Once the case had been analyzed by our specialists, we informed the patient and her relatives about what they could expect with Escozul™ and the possibilities of achieving good results. In this case we hoped to be able to help at least to control and reduce the disease.

Each dose of Escozul™ is personalized, specific to the type of tumor and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Elena started treatment with Escozul™ in March 2017. She was pending to start chemotherapy.

Evolution, Follow-up and Current Results:

Although Elena has been on treatment for a short time, the results so far are promising. In the CT scan performed in July 2017, it could be seen that the primary lesion in the left lung was more or less the same size, but its tumor activity had decreased from SUV 12.4 at the end of February to SUV 2.8 in July. In the neck area only one adenopathy remained, which decreased from 11x18mm and SUV 4.8, to 5x6mm and SUV 1.99 in July. As for the adenopathies in thorax, they decrease from maximum size 10x16mm with an uptake of up to SUV 6.3 in February, to a maximum size of 10x12mm with SUV of 3.26 in July 2017.

On re-examination in July 2017, a decrease in size of the primary lesion from 37mm to 30mm is observed, the adenopathies in the thorax remain stable and the adenopathies in the neck decreased to 14 their largest diameter.

By October 2017, in CT scan performed on Elena, the disease was arrested, with no new lesions appearing and showing reductions in the size of the existing ones. The primary tumor has decreased by about 20% since Elena started treatment and she is in good physical condition.

The results obtained in Elena's case, with the combined use of Escozul™ and chemotherapy, have been very good, as we have managed to reduce the tumor activity of all the cancerous lesions, as well as reducing the size of the lymph node lesions and the primary lung lesion. We still have a long way to go, but we hope that the results will continue to be as good as they have been so far.

We continue the treatment with Escozul™ with the intention of improving the results obtained and that Elena can enjoy many more years of life with her family.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group August/2017

Medical Documents

Carlos is a 66 year old patient, who was diagnosed with microcytic lung cancer, with multiple metastases to the liver, bones, lymph nodes. He came to us in September 2016 looking for an alternative that will help him fight the disease.

Case summary:

We share today the case of a 66-year-old patient who came to us in September 2016, with a diagnosis of advanced stage lung cancer.

When we received the medical documentation we were able to ascertain that Carlos had lung cancer, specifically small cell carcinoma, with multiple metastatic tumor lesions in bone, liver and lymph nodes and a tumor remnant in mediastinum (thorax).

As for symptoms, she presented pain in the lung area, depression, tiredness, weakness, occasional loss of appetite.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results. In this case, given the advanced stage of the disease, we told the family that in these cases the chances of obtaining positive results were not the best due to the extent of the disease.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Carlos started treatment with Escozul™ in September 2016. He was undergoing chemotherapy and radiotherapy, although the chemotherapy was causing leukopenia.

Evolution, Follow-up and Current Results:

During the first three months of treatment Carlos' disease continued to progress and his symptoms continued to be of much fatigue and exhaustion, related to a very strong chemotherapy regimen he was on.

When we received these first analyses, we changed the dosage of the treatment, in order to more effectively combat the disease and help him improve his symptoms. At that time, due to Carlos's physical condition and the effects of the chemo, his oncologist reduced the intensity of the chemotherapies.

Carlos continued the treatment and fortunately when we received the exams after completing 7 months of using Escozul™, the lesions in the lymph nodes and liver had disappeared and the bone lesions showed less tumor activity, the tumor remnant in the mediastinum still persisted.

Carlos's physical condition was much better.

In the September 2017 report, the bone lesions and suspicious lesions in the liver were observed again.

At this time Carlos continues on treatment with Escozul™ with increasing doses, seeking to improve the results obtained and help him to eliminate the little that remains of the disease.

In this case, together with the use of radiotherapy and chemotherapy, we have been able to eliminate the lesions in the lymph nodes and thorax, although we are still working on the bones and liver. As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group July/2017. Updated in December 2017.

Medical Documents

Amparo is a 64 year old patient, who was diagnosed with microcytic lung cancer, with multiple metastases to the brain and abdomen. She came to us in January 2016 looking for a treatment that could offer her better life expectancy, as doctors had given her 3 months to live.

Case summary:

We share today the case of a 64 year old female patient who came to us in January 2016, with a diagnosis of very advanced stage lung cancer with a prognosis of 3 months survival. She is a patient who has been in treatment for a very short time, having just completed 3 months, but in such a short time the combined use of Escozul™ with the treatments offered by conventional medicine has helped Amparo to overcome her life expectancy and present improvements in her condition.

When we received the medical documentation we were able to confirm that Amparo had lung cancer, specifically a small cell neuroendocrine carcinoma, with multiple metastatic tumor lesions in the brain and peritoneum.

As for symptoms, pain in the abdomen, constipation, loss of appetite and weight, abdominal distension or fluid retention.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results. In this case, given the poor prognosis of the patient, we told the family that in such advanced cases good results are not always obtained and that Escozul™ also needs time to act and that it must have at least 3 months of continuous use for there to be any possibility of having effects on the patient.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Amparo started treatment with Escozul™ in early February 2017. She had previously received radiotherapy and was pending to start chemotherapy.

Evolution, Follow-up and Current Results:

Small cell (microcytic) lung cancer is considered the most aggressive form of lung cancer with a high likelihood of spread. In this case the patient came to us at a very advanced stage with a poor short-term prognosis for life that greatly limited the possible effects of treatment.

In March, a little over a month into treatment, we received comments from the family about Amparo's health status. We were told that the evolution was going very well, that she was undergoing chemotherapy with practically no side effects, and that she was no longer retaining liquids and had no swelling.

At the end of April, two and a half months after treatment, we received the results of a new brain MRI, which showed that there had been a significant decrease in the size of the brain lesions, and that the intraparenchymal lesions visualized in the previous study were not observed.

Although very little time has passed since the beginning of the treatment, in this case, with the combined use of Escozul™ and conventional treatments, it has been possible to act initially on the tumor lesions in the brain, which represented an important threat to Amparo's life, to improve her symptoms and tolerance to chemotherapy and to give her hope for the fight. Reports from the thorax and abdomen are still pending to see how the disease has been behaving at those levels.

At this moment Amparo continues on treatment with Escozul™ with increasing doses, seeking to improve the results obtained and help her to have a better quality of life and better survival expectancy.

In this case, together with the use of radiotherapy and temozolamide, we have been able to eliminate the residual brain lesion, eliminating the symptoms so that Amparo can have a normal life and improving her prospects of survival.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2017

Medical Documents

Case Summary:

The case we share today is about a 51-year-old patient who came to us in November 2014, with a diagnosis of metastatic lung cancer. To respect his privacy, we are going to refer to him by the initials of his name: B.F.

When we received the medical documentation we were able to ascertain that it was a primary non-small cell lung cancer, specifically a well-differentiated mucinous adenocarcinoma, with tumor mass in the left upper lobe that was larger than 5.4cm in diameter and had increased in size in recent months. It also presented metastasis to mediastinal and hilar nodes.

At the time of case evaluation, B.F. was in stage III and presented morning cough with hemoptotic expectoration.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

B.F. started treatment with Escozul™ in early December 2014. She was undergoing chemotherapy.

Evolution, Follow-up and Current Results:

In many occasions the response to treatment with Escozul™ is not a straight line, there are moments of regression of the disease and some moments of progression in which we take measures to bring the disease back under control.

In B.F.'s case, at the beginning of treatment, the primary tumor in the lung measured 5.3×5.4cm and had metastasis to nodes in the mediastinum and hilar nodes.

In April we received notification that the patient felt well physically and had no respiratory symptoms, no cough or expectoration.

In August 2015 tomography the mediastinal adenopathies (nodes) remained stable, the primary tumor measured 5.5x3cm, which implied a reduction of approximately 40% with respect to the start of treatment, but some pulmonary nodules compatible with metastasis were observed. The hilar adenopathies had disappeared.

B.F.'s physical condition remained good and we continued with a progressive dose escalation schedule.

In the March 2017 CT scan, 2 years and 3 months after treatment with Escozul™, the tumor measured 2.4×1.5cm, implying an 80% reduction of the initial size of the primary tumor. The other tumor nodules in the lungs had disappeared, and the mediastinal adenopathy had reduced in size.

In two years of treatment, the size of the lung lesion had been greatly reduced, most of the other tumor lesions had been eliminated and the disease had been kept under control. B.F. has no symptoms of the disease.

On examination in late June 2017, everything continued to be stable. In January 2018, new examination shows that the disease was stable and there were no new lesions.

We continue the treatment with Escozul™ with the intention of maintaining and improving the results obtained, in order to contribute to B.F. being able to continue fighting the disease and having as normal a life as possible.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group January/2017

Medical Documents

Case summary:

Esthela is a 69-year-old patient, who was diagnosed in late 2015 with a right lung cancer with metastases in multiple locations, including in brain, which had been treated with chemo and radiotherapy.

When we received the medical documentation we were able to ascertain that it was a primary lung cancer with right apical tumor mass of 4.5×3.2×2.2 cm that had increased in size in the last two months, despite the patient being receiving chemotherapy.

At the time of case evaluation, she presented with right shoulder pain, needed medication to sleep, and was going through a period of depression.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results. In this case, we hoped to contribute to the stability and decrease of the disease.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Esthela started treatment with Escozul™ in June 2016. She was undergoing radiotherapy treatment and pending further chemotherapy.

Evolution, Follow-up and Current Results:

During the time of treatment Esthela has remained in good physical condition, despite the various treatments she has undergone. In July 2016, new CT scan reported decrease in tumor size to 3.4×1.9×2.5.

The latest CT results in January 2017 indicated further decrease in tumor size to 3×1.4×2 cm. Since the start of treatment, the tumor has decreased by 73.5% in size, demonstrating once again, that the joint use of Escozul™ with other therapies not only helps the patient to feel better but also to have better results.

In CT in June 2017, the pulmonary nodule, which is the only one that persists, remains stable in size, but its localized metabolic activity decreased from 3.2 to 1.9, so it is considered that at this time the nodule has no malignant tumor activity.

The results have been very positive, since we have been able to reverse the increase in size of the lesion that was being observed in the patient in spite of the chemotherapy treatment, in addition to inactivating its tumor activity.

We continue with a scheme of progressive dose increase, with the intention of maintaining these results and improving them, in order to contribute to Esthela being able to continue fighting the disease and enjoying her family.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only by working together and constant communication, it is possible to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group January/2017

Medical Documents

Case summary:

The first step was the analysis of the medical documentation. Our team was able to conclude that Maria presented with a cancer in the right lung, confirmed by biopsy as poorly differentiated non-small cell carcinoma, which indicated that this was an aggressively growing type of cancer. At that time the disease had spread to lymph nodes in the right pulmonary hilum, subcarinal, middle mediastinum, right pre and paratracheal region.

As physical symptoms, Maria reported fatigue.

We informed the family about these findings and about the possible results that treatment with Escozul™ could offer in terms of improving her quality of life and containing the disease.

Maria was started on Escozul™ at the end of November and it was suggested to do the chemotherapy she had indicated as no treatment should be abandoned for another.

Evolution, follow-up and current results:

In February, after 3 months of treatment, we received the first report on Maria's health. Physically, despite the chemotherapy and its side effects, the patient was doing well. The PET/CT result was revealing. Maria's primary lesion had shrunk by 34%. The lymph node metastases had also decreased in size.

We then decided to maintain a progressive dose increase, always seeking not only to maintain, but to improve the results achieved.

In a new full body PET/CT study performed in July, 7 months after starting Escozul™, the primary lesion in the lung is stable in size, with no significant metabolic activity. Lymph node lesions

In a new CT scan in November 3 months later, a 50% reduction of the primary pulmonary lesion in the apical segment of the LID, and of the lesion adjacent to the vein, was observed with respect to the analysis of a year ago.

There is also almost complete regression of the right paratracheal and right hilar lymph node involvement. No further lymph node involvement is observed.

Conclusions:

The results in Maria are excellent. After one year of treatment with Escozul™ she has practically eliminated the lymph node metastases, in addition to reducing the size of the tumor lesions by 50%. It is true that there is still a long way to go, but these results in themselves represent a better life expectancy for Maria.

Maria does not present any physical symptoms of the disease, which also means that her quality of life is good and she can have a normal life, which is something so precious for every cancer patient and their families.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com . If you would like to learn more about Escozul™ and our work you can find information on this website.

Medical Documents

Initial Diagnosis:

Primary tumor, 2.5 cm mass in the upper lobe of the right lung.

Patient's condition before starting treatment:

- Mild cough.

Treatments received:

Chemotherapies and radiotherapy.

Analysis to determine dose and concentration of Escozul™:

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account. Recommended dose: 200 ml daily at 0.36 mg/ml.

A copy of this evaluation is sent to the patient and family members. Start Escozul™ in February 2014 along with chemotherapy, according to the progression of the disease and the patient's symptoms.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It works on many types of cancer, with best results in solid tumors, effectiveness depends on the type of cancer and the degree of disease progression. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Current results:

May report: Mass: 2.2×2.3×1.9 cm, with metastatic lymphadenopathy in mediastinum (1.3×2.2cm nodule). We continued to increase the dose of the drug in order to improve the results.

After almost 9 months of treatment we received information on the evolution of the case, in Eduardo's own words:

"Ariel how are you, I wanted to give you the news that I had the PET scan, the result thanks God is very good, the primary tumor was reduced, it is almost negative, the metastasis of the mediastinum disappeared so the treatment has been a success now only remains to operate to remove the primary tumor of the lung and God willing I will be cured. I think I should continue taking the medication but you will tell me what to do. Well, a big hug and infinite gratitude".

Effects of Escozul™:

- Increased appetite.

- During chemo only discomfort when swallowing and some decay; No loss of appetite; No decrease in defenses.

In December, in biopsy of primary tumor prior to surgery, it was negative for malignant cells. In Eduardo's words: "Let me tell you that yesterday I had the consultation with the oncologist and the surgeon, they gave me the result of the biopsy and everything is negative, even the primary tumor was negative (fibrous tissue with infiltration of giant cells)".

Summary:

The keys to Eduardo's recovery are undoubtedly the early detection, the speed with which he contacted us, and his discipline and constancy both in taking the medication and in being in contact all the time to modify the dose according to his evolution.

Eduardo followed a program designed according to the type of cancer where he had gradual increases in concentration in order to reduce the tumor and the metastasis. And although there is still a long way to go, being in this position right now is undoubtedly an advantage. The result is undoubtedly positive, since the tumor was completely eliminated. The constant contact between the patient and our team, which had a decisive influence in achieving these results, allowed us to make adjustments to the dose, which in turn had an impact on the disease.

Medical Documents

Initial Diagnosis:

Stage IV operated lung cancer, with prevascular, paratracheal, paratracheal, subcarinal, hilar, right and left supraclavicular lymph node metastases, infiltration to adrenal glands.

Patient's condition before starting treatment:

• - Pain in left clavicle.
• - Difficulty sleeping.

Treatments:

Started with Escozul™ in September 2014. Subsequently started with chemotherapy.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Current results:

Chest and abdominal scan at 6 months of treatment showed disappearance of subcarinal and hilar lymph node metastases and paratracheal metastases decreased in size. No adrenal involvement was observed.

Improvement in the quality of life has also been achieved, as well as regression of the disease at different levels. Side effects of chemo have been minimal.

In May 2016, one year and 9 months after starting Escozul™, Luis underwent full body exams to know the status of the disease and if there was any new tumor focus. No malignant cells were observed in any location in the body.

At this time, 2 years after starting Escozul™, Luis is cancer free, and continues to have check-ups every 6 months. We continue with progressive doses of Escozul™, to maintain these results and try to prevent the appearance of new lesions.

Summary:

The patient continues to consume Escozul™ with progressive doses in search of maintaining these results.

The patient is leading a normal life with his family, without the disease affecting his activities and physical and mental well-being.

Medical Documents

Initial Diagnosis:

Non-small cell lung cancer (poorly differentiated squamous cell carcinoma) IIIB, with mediastinal node involvement.

Patient's condition before starting treatment:

• - Loss of appetite
• - Nausea
• - Cough
• - Mild fever

Treatments:

Started on Escozul™ in August 2015. The patient had received one session of chemotherapy and 4 fractions of radiotherapy in July, which was suspended due to febrile response and the patient decided to abandon those treatments.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

In these first three months of treatment the patient has improved her physical condition. In view of this improvement, in mid-October she decided to go to the doctor to evaluate the possibility of resuming treatment.

Two months after starting treatment with Escozul™, a CT scan of the thorax was performed, showing a decrease in the primary lesion in the lung.

In this case, the patient's physical condition has improved and the disease has been reduced. Given her physical improvement, the patient has been able to resume radiotherapy treatment.

Summary:

In this case the patient has had a rapid and very positive response to treatment. It is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease. This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents

Initial Diagnosis:

Lung cancer (bronchogenic carcinoma, 5×4.8cm) IV with brain metastasis and cervical and mediastinal lymph node involvement.

Treatments:

He was started on Escozul™ in early February 2015. He was not receiving any treatment by personal choice.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

In mid-March 2015, stability of the disease at lung level was evidenced in tomography.

The CT scan in May reveals a decrease of the primary tumor in the lung, with slight growth of the lymph node involvement. In July there was evidence of a decrease in the size of the tumor lesion. The examination of July 20 reports a decrease in the lung tumor mass to 4.6×3.5cm, and stability in the lymph node metastases.

During the following months of 2015, SP's analytical tests remained in normal ranges, without presenting any change in his physical condition.

In CT and MRI scans performed in February 2016, moderate regression of brain lesions was observed, although with a slight increase in lung mass and lymph node lesions, so a dose readjustment was immediately performed. SP continued without physical evidence of disease.

A new MRI performed in June 2016, showed stability in the only brain lesion.

In a new PET-CT scan performed in July 2016, complete regression of the disease was observed, with no pulmonary or lymph node tumor lesions, only a slight right pulmonary enhancement was observed.

In PET-CT of December 2016, no change was observed with respect to July, maintaining the right pulmonary enhancement.

In PET-CT of October 2017, the examination concludes that: "No metabolic lesions suggesting the presence of macroscopic tumor activity are appreciated". This indicates that after 2 years and 8 months of treatment with Escozul™ in conjunction with other treatments, it has been possible to at least reduce the size of the lesions so that they are not detectable by PET-CT. This is a positive result that undoubtedly broadens the prospects of survival of SP, despite being a type of cancer that had already advanced to the brain more than two years ago.

SP's analytical tests have remained stable and within normal parameters throughout the treatment period, despite having undergone chemotherapy and immunotherapy treatments on several occasions.

In conjunction with conventional treatments, SP has been helped to eliminate pulmonary and ganglion lesions and to reduce and maintain stable brain involvement, maintaining an excellent quality of life, with no evidence of neoplastic disease.

Medical Documents

Initial Diagnosis:

54-year-old Carmen came to us in May 2015, seeking alternative treatment for her disease. She had previously suffered from breast cancer, which always involves a risk of relapse and after 6 months of feeling severe pain in her spine, when she went to the doctor she was found to have tumor lesions in multiple bones.

We received Carmen's medical documents in which we were able to verify that she had lymph node involvement in thoracic ganglions, pulmonary nodules in the right lower lobe, in addition to malignant tumor lesions in the right femur, right sacroiliac and multiple lesions in the spine. It was later demonstrated that it was a new primary cancer, in this case a stage IV adenocarcinoma of the lung. The prognosis of the case was guarded.

Patient's condition before starting treatment:

- Carmen also presented with pain in the spine and upper right leg, which made it difficult for her to sleep well.

Treatments:

With all this information we proceeded to give an assessment of the case to the family and what could be expected from the treatment indicating concrete results.

In May 2015 Carmen started with Escozul™ in conjunction with chemotherapy.

Evolution, Follow-up and Current Results:

Two weeks into treatment, Carmen was doing well overall, referring only a little more fatigue, despite having started chemotherapy as well.

In July we received the following report, indicating that the patient was doing well in general, with good appetite and a relatively normal life. Secondary to the chemo she had presented some skin reactions, which were treated symptomatically. In August the family informed us that the tests performed on Carmen showed that the disease was stable. Carmen continued in good physical condition.

According to a CT scan performed in November 2015, the lymph node involvement in the thorax had disappeared. The primary lesion in the lung was not observed either.

In February 2016, Carmen's sister told us that the results have been very good despite the advanced stage of the disease and that the doctors are amazed that Carmen has not declined and how the response has been at the pulmonary level.

In April 2016, almost a year after treatment, a new bone scintigraphy gives as a result that there has been a practically total regression of all the bone metastases that Carmen was suffering from.

Conclusions:

Every patient facing a stage IV cancer diagnosis receives palliative treatment options, which means they are to help keep the disease from escalating, and to help her have a better quality of life. In cases such as this, achieving a reduction in tumor lesions and even eliminating them is a very promising result that leads to a considerable increase in the patient's life expectancy; together with the improvement in quality of life, this means that the patient can enjoy quality time with his or her family, without the threat of an imminent outcome. The use of Escozul™ has helped Carmen to be able to achieve these goals and to continue to enjoy a practically normal life, despite the fatal diagnosis she received more than a year ago.

As we always say, it is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com . If you would like to learn more about Escozul™ and our work you can find information on this website.

Medical Documents

Initial Diagnosis:

Lung cancer with metastasis to mediastinal nodes.

Patient's condition before starting treatment:

• - Frequent cough
• - Shoulder and leg pain making it difficult to eat and rest at night.

Treatments:

Started on Escozul™ in October 2013, at the same time as starting treatment with chemotherapy. Due to the outlook for the type of cancer, the family decided to look for alternative options early on that could increase life expectancy and improve the patient's quality of life.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Case evolution:

After the first 4 months of treatment with Escozul™, the patient underwent CT scan which showed "Significant regression of the disease when compared to the previous CT scan of September 11, 2013".

The pain in the legs had disappeared, which improved the quality of the patient's rest and eating, the cough was reduced to occasional moments, mostly in the morning and the patient reported feeling well in general.

By April 2014 the chest CT scan, showed improvement from January and all blood tests were normal, and the patient continued to feel well.

continued to feel well.

In July, a new CT scan showed a slight increase in tumor size, which was counteracted by an increased dose of Escozul™. A new CT scan in December 2014 detected that the tumor was equal to its situation in April 2014, implying new regression. Scar tissue markings were observed in the lungs, in areas previously affected by the cancer. The patient continues to feel physically well and to carry out his daily activities, even being able to take walks.

Current results:

As of February 2015, at the patient's last report, he continued to feel well, and blood results were within normal limits. The patient continues to consume Escozul™ at progressive doses in pursuit of maintaining these results.

Summary:

It has been achieved in this case, reducing the disease and preventing its progression. In addition, the patient's quality of life has been restored, ensuring that he can lead a normal life, despite the disease.

Medical Documents

Initial Diagnosis:

We received the case documentation and our team performed the analysis and dose determination. We noted from the paperwork that this was a primary lung cancer, with a biopsy result of poorly differentiated carcinoma.

The primary tumor was not clearly seen in the results due to the presence of extensive pleural effusion. There were metastases to the pleura and also to the lymph nodes, with adenopathies in the mediastinum and right hilum. There was also vertebral bone metastasis at L4.

Patient's condition before starting treatment:

In terms of symptoms he referred cough, and an anxious mood due to worry and uncertainty of his disease.

Treatment with Escozul™:

We explained to the family Teresa's condition and the possibilities of response to treatment with Escozul™. We designed a high dose with the objective of attacking the disease and increasing her survival time with quality.

Teresa started treatment with Escozul™ in March 2016, she was pending to start chemotherapy.

Current results:

During the time of treatment Teresa has remained stable, she has not presented pain, or any other symptoms associated with the disease and her mood has improved. She only reports mild stomach discomfort associated with oral chemotherapy.

In a new CT scan of the chest, abdomen and pelvis, performed in July 2016, 4 months after starting treatment with Escozul™, the multiple lymph node and nodular metastases that appeared in the previous CT scan (February 2016) are no longer observed, there is no pleural effusion and no metastases have appeared in other organs. Bone involvement at L4 is also not observed. Regarding the primary lesion, it is not possible to compare whether it is larger, smaller or equal, because in the first examination it was not observed due to the extensive pleural effusion.

In a case like this, where the disease was discovered at an advanced stage and due to the type of cancer, the chances of improvement were low, the fact of having managed to eliminate metastatic lesions is a considerable achievement. Teresa's health status has improved rather than worsened, and this means that her quality of life and survival time are greater now than when she was diagnosed.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, scozul does not work miracles. Only by working together and constant communication, it is possible to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com . If you wish to learn more about Escozul™ and our work you can find information on this website.

Medical Documents